Abstract
Photodynamic therapy (PDT) involves the use of topically applied aminolevulinic acid (ALA), in conjunction with a light sensitizer, to generate reactive oxygen species in the skin. Currently, the only FDA-approved indication for ALA-based PDT is for the treatment of actinic keratoses. However, through a review of the medical literature, it has been found that dermatologists and dermasurgeons alike have, through off-label uses, expanded the possibilities for treatment of a variety of conditions, which include cutaneous oncology and cosmetic dermasurgery. These off-label uses of ALA-PDT include photorejuvination and the treatment of Barrett9s esophagus, Paget9s disease, acne vulgaris, psoriasis, sebaceous gland hyperplasia, rosacea, and hirsutism.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
